RIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT™ SYSTEM
Study to assess safety and effectiveness of a minimally invasive, zero-capital,outpatient device therapy for BPH Rivermark Medical, a urology-focused medical device company committed to redefining benign prostatic hyperplasia (BPH) treatment through simple, innovative solutions, today announced the enrollment of the first patient in its RAPID III clinical study. RAPID III is a prospective, multicenter, randomized […]